Cindy Madden

776 total citations · 1 hit paper
9 papers, 598 citations indexed

About

Cindy Madden is a scholar working on Immunology, Pathology and Forensic Medicine and Infectious Diseases. According to data from OpenAlex, Cindy Madden has authored 9 papers receiving a total of 598 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Immunology, 4 papers in Pathology and Forensic Medicine and 3 papers in Infectious Diseases. Recurrent topics in Cindy Madden's work include Psoriasis: Treatment and Pathogenesis (5 papers), Autoimmune Bullous Skin Diseases (4 papers) and Antifungal resistance and susceptibility (3 papers). Cindy Madden is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (5 papers), Autoimmune Bullous Skin Diseases (4 papers) and Antifungal resistance and susceptibility (3 papers). Cindy Madden collaborates with scholars based in Canada, Germany and United States. Cindy Madden's co-authors include Veerle Vanvoorden, Andrew Blauvelt, Kristian Reich, Mark Lebwohl, Nancy Cross, Diamant Thaçi, Nina Magnolo, Andreas Pinter, Christopher L. Cioffi and Richard G. Langley and has published in prestigious journals such as Annals of Emergency Medicine and SKIN The Journal of Cutaneous Medicine.

In The Last Decade

Cindy Madden

9 papers receiving 566 citations

Hit Papers

Risk of myocardial infarction and death during treatment ... 1991 2026 2002 2014 1991 100 200 300 400 500

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Cindy Madden Canada 4 481 200 188 109 55 9 598
Mark D. Cohen United States 7 364 0.8× 227 1.1× 87 0.5× 121 1.1× 6 0.1× 9 492
Kerry Kaplan United States 12 309 0.6× 123 0.6× 53 0.3× 92 0.8× 10 0.2× 19 463
Hercules E. Mavrakis Greece 17 1.5k 3.0× 90 0.5× 68 0.4× 75 0.7× 17 0.3× 41 1.6k
Yong‐Soo Baek South Korea 15 645 1.3× 114 0.6× 86 0.5× 119 1.1× 13 0.2× 64 732
Hasan Arı Türkiye 11 444 0.9× 150 0.8× 59 0.3× 74 0.7× 13 0.2× 69 516
William M. Byra United States 9 430 0.9× 57 0.3× 94 0.5× 49 0.4× 9 0.2× 16 510
Damirbek Osmonov Türkiye 14 270 0.6× 95 0.5× 32 0.2× 45 0.4× 13 0.2× 35 445
Özcan Özdemır Türkiye 13 351 0.7× 85 0.4× 37 0.2× 33 0.3× 13 0.2× 45 562
John Cannon United Kingdom 12 353 0.7× 143 0.7× 191 1.0× 17 0.2× 18 0.3× 36 672
Serkan Öztürk Türkiye 15 315 0.7× 96 0.5× 33 0.2× 58 0.5× 9 0.2× 65 551

Countries citing papers authored by Cindy Madden

Since Specialization
Citations

This map shows the geographic impact of Cindy Madden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cindy Madden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cindy Madden more than expected).

Fields of papers citing papers by Cindy Madden

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cindy Madden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cindy Madden. The network helps show where Cindy Madden may publish in the future.

Co-authorship network of co-authors of Cindy Madden

This figure shows the co-authorship network connecting the top 25 collaborators of Cindy Madden. A scholar is included among the top collaborators of Cindy Madden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cindy Madden. Cindy Madden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Reich, Kristian, Andrew Blauvelt, Mark Lebwohl, et al.. (2021). Bimekizumab Safety in Patients with Moderate to Severe Psoriasis: Analysis of Pooled Data from Phase 2 and 3 Clinical Trials. SKIN The Journal of Cutaneous Medicine. 5(1). s21–s21. 1 indexed citations
2.
Strober, Bruce, Nina Magnolo, Ronald Vender, et al.. (2021). Bimekizumab versus Ustekinumab Efficacy Across Subgroups of Patients with Moderate to Severe Plaque Psoriasis: Results from the Multicenter, Randomized, Double-Blinded Phase 3 BE VIVID Trial. SKIN The Journal of Cutaneous Medicine. 5(1). s16–s16. 1 indexed citations
3.
Reich, Kristian, Kim Papp, Andrew Blauvelt, et al.. (2020). Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE VIVID, a 52-Week Phase 3, Randomized, Double-Blinded, Ustekinumab- and Placebo-Controlled Study. SKIN The Journal of Cutaneous Medicine. 4(6). s82–s82. 3 indexed citations
4.
Gordon, Kenneth B., Peter Foley, Andreas Pinter, et al.. (2020). Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE READY, a 56-Week Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study with Randomized Withdrawal. SKIN The Journal of Cutaneous Medicine. 4(6). s83–s83. 2 indexed citations
5.
6.
Madden, Cindy. (1991). Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Annals of Emergency Medicine. 20(2). 213–214. 533 indexed citations breakdown →
7.
Madden, Cindy. (1991). A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures. Annals of Emergency Medicine. 20(2). 213–213. 37 indexed citations
8.
Madden, Cindy. (1991). Evidence that histamine is the causative toxin of scombroid fish poisoning. Annals of Emergency Medicine. 20(10). 1164–1164. 16 indexed citations
9.
Madden, Cindy. (1991). Regular inhaled beta-agonist treatment in bronchial asthma. Annals of Emergency Medicine. 20(7). 824–825. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026